Abstract 5043
Background
Neoadjuvant therapy for breast cancer has been increasingly used in recent years as first-line treatments for breast cancer. A high lymphocytic infiltration is known to correlate with response to neoadjuvant chemotherapy and prognosis, however little attention has been paid to changes in CD8+, CD4+, FOXP3+ immune call profiles during perioperative chemotherapy.
Methods
Treatment results of 43 patients with TNBC stages IIB-IIIB homogeneously treated with neoadjuvant chemotherapy were analyzed. We studied the baseline and post-treatment FOXP3+, CD4+, CD8+ tumor-infiltrating immune cells by immunohistochemistry. Therapeutic pathomorphism was evaluated in terms of the residual tumor burden identification (RCB) (using Miller-Payne classification). Variables distribution was scored using ANOVA test. Survival probabilities were estimated by the Kaplan-Meir method. Hazard ratios and their 95% confidence interval were calculated with the Cox proportional hazards model.
Results
Pathological complete response (pCR) to neoadjuvant chemotherapy was identified in 12% of patients. In group without pCR high baseline levels of the stromal CD4+ cells were identified in 39,4% of patients, peritumoral CD4+ cells – in 44,7%; high levels of stromal CD8+ cells were identified in 28% and peritumoral CD8+ – in 52% of patients; and high levels of FOXP3+ were identified 47,3% of patients. The levels of CD8+ and FOP3+ cells decreased during treatment in 13% of patients. The levels of peritumoral CD4+ cells deceased during treatment in 34, % of patient, whereas levels of stromal CD4+ increased during treatment in 10,6% of patients. We found that in the population with residual disease after neoadjuvant chemotherapy the high baseline levels of peritumoral CD4+ immune cells were strongly associated with adverse outcome (HR 3,33, CI 1,29 – 8,58; p = 0,013).
Conclusions
The high baseline levels of peritumoral CD4+ lymphocytes in triple negative breast cancer tumor failing to achieve pCR were associated with adverse outcome. Further studies are required for identifying patients who are likely to benefit from immunotherapeutic adjuvants to conventional treatment approaches.
Clinical trial identification
Legal entity responsible for the study
National Cancer Institute, Ukraine, Kiev.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract